Li X M, Huang C K, Zhang T F, Teper A A, Srivastava K, Schofield B H, Sampson H A
Department of Pediatrics, Mt Sinai School of Medicine, New York, NY 10029-6574, USA.
J Allergy Clin Immunol. 2000 Oct;106(4):660-8. doi: 10.1067/mai.2000.110102.
Asthma is a major public health problem worldwide, and the morbidity and mortality of asthma have increased in the past two decades. The reputed efficacy, low cost, and relative absence of side effects of traditional Chinese medicines (TCMs) have led to increasing interest in the use of TCMs for the treatment of asthma in Western countries. However, there are few well-controlled scientific studies on the efficacy, safety, and mechanisms of action of TCMs used to treat asthma.
The goal of this study was to investigate the effects of the Chinese herbal medicine formula MSSM-002, derived from TCMs used to treat allergic asthma, on a well-characterized mouse model of allergic asthma.
Mice sensitized intraperitoneally and challenged intratracheally with conalbumin were treated with MSSM-002 24 hours after the first intratracheal challenge. Dexamethasone-treated, saline solution sham-treated, and naive mice served as controls. The effects of MSSM-002 on allergic airway hyperreactivity, inflammation, antigen-specific antibody production, lung histologic features, and cytokine profiles were evaluated.
MSSM-002 treatment virtually eliminated airway hyperreactivity and markedly reduced the total number of cells and the percent eosinophils in bronchoalveolar lavage fluids compared with the sham-treated group. Lung histologic features showed that MSSM-002 reduced inflammation and mucus production. These effects were equivalent to the effects of dexamethasone, but in contrast to the overall immunosuppressive effects of dexamethasone MSSM-002 treatment decreased antigen-specific IgE, IL-4, IL-5, and IL-13 levels without suppressing IgG2a and IFN-gamma synthesis.
MSSM-002 exhibits anti-airway hyperresponsiveness, anti-airway inflammation, and immunoregulatory effects on T(H)1/T(H)2 responses, which may be useful for treatment of allergic asthma.
哮喘是全球主要的公共卫生问题,在过去二十年中哮喘的发病率和死亡率有所上升。中药因其公认的疗效、低成本以及相对较少的副作用,在西方国家越来越受到关注,被用于治疗哮喘。然而,关于用于治疗哮喘的中药的疗效、安全性和作用机制,鲜有严格对照的科学研究。
本研究旨在探讨源自用于治疗过敏性哮喘的中药的草药配方MSSM - 002对特征明确的过敏性哮喘小鼠模型的影响。
用卵清蛋白腹腔致敏并经气管内激发的小鼠,在首次气管内激发后24小时用MSSM - 002治疗。地塞米松治疗组、生理盐水假治疗组和未处理的小鼠作为对照。评估MSSM - 002对过敏性气道高反应性、炎症、抗原特异性抗体产生、肺组织学特征和细胞因子谱的影响。
与假治疗组相比,MSSM - 002治疗几乎消除了气道高反应性,并显著降低了支气管肺泡灌洗液中的细胞总数和嗜酸性粒细胞百分比。肺组织学特征显示,MSSM - 002减轻了炎症和黏液分泌。这些作用与地塞米松相当,但与地塞米松的整体免疫抑制作用相反,MSSM - 002治疗降低了抗原特异性IgE、IL - 4、IL - 5和IL - 13水平,而不抑制IgG2a和IFN - γ的合成。
MSSM - 002对气道高反应性、气道炎症具有抑制作用,并对Th1/Th2反应具有免疫调节作用,可能对过敏性哮喘的治疗有用。